{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:29:39Z","timestamp":1776702579471,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Fight against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106941","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:49:46Z","timestamp":1775753386000},"page":"106941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-0781","authenticated-orcid":false,"given":"I.","family":"Dirven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7096-476X","authenticated-orcid":false,"given":"C.","family":"Bertels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8674-4085","authenticated-orcid":false,"given":"Y.","family":"Moreels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.I.","family":"Kessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-6611","authenticated-orcid":false,"given":"N.","family":"Vanlaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-S.","family":"Vander Mijnsbrugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-8390","authenticated-orcid":false,"given":"M.","family":"Vounckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-0358","authenticated-orcid":false,"given":"I.","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4544-7001","authenticated-orcid":false,"given":"L.","family":"Raes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-9482","authenticated-orcid":false,"given":"X.","family":"Geeraerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-541X","authenticated-orcid":false,"given":"B.","family":"von Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fasolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-0430","authenticated-orcid":false,"given":"G.","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-3906","authenticated-orcid":false,"given":"T.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Caljon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Everaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rogiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5714-3254","authenticated-orcid":false,"given":"J.","family":"Vandemeulebroucke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-8071","authenticated-orcid":false,"given":"S.","family":"Tuyaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-5903","authenticated-orcid":false,"given":"B.","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2026.106941_bib1","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Warner","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106941_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106941_bib3","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","article-title":"Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling","volume":"11","author":"Adamopoulos","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106941_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","article-title":"Durable suppression of acquired MEK inhibitor resistance in cancer by sequestering MEK from ERK and promoting antitumor T-cell immunity","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-015-0293-5","article-title":"Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma","volume":"14","author":"Atefi","year":"2015","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106941_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2026.106941_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2019.03.037","article-title":"Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging","volume":"453","author":"Liu","year":"2019","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106941_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/CMR.0000000000000977","article-title":"Regorafenib in patients with pretreated advanced melanoma: a single-center case series","volume":"34","author":"Vander Mijnsbrugge","year":"2024","journal-title":"Melanoma Res"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106941_bib10","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.3390\/cancers16234083","article-title":"Regorafenib combined with BRAF\/MEK inhibitors for the treatment of refractory melanoma brain metastases","volume":"16","author":"Dirven","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106941_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","article-title":"c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis","volume":"157","author":"Steeb","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106941_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/bjd\/ljae401","article-title":"Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma","volume":"192","author":"McGillivray","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.esmoop.2026.106941_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100756","article-title":"Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: a systematic review and meta-analysis","volume":"3","author":"Pham","year":"2025","journal-title":"EJC Skin Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106941_bib14","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0959-8049(22)01025-5","article-title":"A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: a Multicenter Trial of Korean Cancer Study Group (UN-14\u201313)","volume":"174","author":"Kim","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106941_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106941_bib16","series-title":"Cancer Fact Sheets 2022","year":"2024"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib17","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106941_bib18","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1634\/theoncologist.2019-0033","article-title":"Phase II trial of continuous regorafenib dosing in patients with gastrointestinal stromal tumors after failure of imatinib and sunitinib","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib19","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1038\/s41598-017-09132-1","article-title":"Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients","volume":"7","author":"Schvartsman","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106941_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106941_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial\u2014ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106941_bib22","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-15-0136-T","article-title":"Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors","volume":"14","author":"Whittaker","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"9863","key":"10.1016\/j.esmoop.2026.106941_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106941_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CMR.0000000000000415","article-title":"Illustrative cases for monitoring by quantitative analysis of BRAF\/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy","volume":"28","author":"Seremet","year":"2018","journal-title":"Melanoma Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106941_bib26","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.3390\/cancers15164083","article-title":"Development and validation of a predictive model for metastatic melanoma patients treated with pembrolizumab based on automated analysis of whole-body [18F] FDG PET\/CT imaging and clinical features","volume":"15","author":"Dirks","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:33:00Z","timestamp":1776699180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008835"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106941","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106941"}}